Drug General Information
Drug ID	D0OC4O
Former ID	DNCL002462
Drug Name	RG7388
Drug Type	Small molecular drug
Indication	Hematological malignancies [ICD9: 200-209; ICD10:C81-C86]		Phase 1	[525138]
Company	Roche
Structure		Download 2D MOL 3D MOL
Formula	C31H29Cl2F2N3O4
PubChem Compound ID	53358942
Target and Pathway
Target(s)	Ubiquitin-protein ligase E3 Mdm2	Target Info	Modulator	[533203]
	Receptor protein-tyrosine kinase erbB-4	Target Info	Inhibitor	[543487]
KEGG Pathway	FoxO signaling pathway
	Cell cycle
	p53 signaling pathway
	Ubiquitin mediated proteolysis
	Endocytosis
	PI3K-Akt signaling pathway
	Thyroid hormone signaling pathway
	Epstein-Barr virus infection
	Pathways in cancer
	Transcriptional misregulation in cancer
	Viral carcinogenesis
	Proteoglycans in cancer
	MicroRNAs in cancer
	Glioma
	Prostate cancer
	Melanoma
	Bladder cancer
	Chronic myeloid leukemiahsa04012:ErbB signaling pathway
	Calcium signaling pathway
PANTHER Pathway	Insulin/IGF pathway-protein kinase B signaling cascade
	p53 pathway
	Ubiquitin proteasome pathway
	P53 pathway feedback loops 1
	p53 pathway feedback loops 2P00004:Alzheimer disease-presenilin pathway
	Cadherin signaling pathway
	EGF receptor signaling pathway
Pathway Interaction Database	ErbB4 signaling events
	p73 transcription factor network
	ATR signaling pathway
	ATM pathway
	Glucocorticoid receptor regulatory network
	Sumoylation by RanBP2 regulates transcriptional repression
	Direct p53 effectors
	Regulation of Androgen receptor activity
	Validated transcriptional targets of deltaNp63 isoforms
	Aurora A signaling
	Validated transcriptional targets of TAp63 isoforms
	p53 pathway
	Regulation of retinoblastoma protein
Reactome	AKT phosphorylates targets in the cytosol
	Oxidative Stress Induced Senescence
	Oncogene Induced Senescence
	Trafficking of AMPA receptors
	Constitutive Signaling by AKT1 E17K in Cancer
	Stabilization of p53
WikiPathways	DNA Damage Response (only ATM dependent)
	DNA Damage Response
	ErbB Signaling Pathway
	Senescence and Autophagy in Cancer
	Tryptophan metabolism
	G1 to S cell cycle control
	Copper homeostasis
	Bladder Cancer
	Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
	PIP3 activates AKT signaling
	Apoptosis
	ATM Signaling Pathway
	Retinoblastoma (RB) in Cancer
	Integrated Pancreatic Cancer Pathway
	Prostate Cancer
	Signaling Pathways in Glioblastoma
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Cell Cycle
	Cell Cycle Checkpoints
	TP53 Network
	miRNA Regulation of DNA Damage Response
	Androgen receptor signaling pathwayWP673:ErbB Signaling Pathway
	EV release from cardiac cells and their functional effects
References
Ref 525138	ClinicalTrials.gov (NCT02407080) Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia. U.S. National Institutes of Health.
Ref 533203	Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21.
Ref 543487	(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.